SCHEMBL3971627

SCHEMBL3971627

Cc1nnc(C)c(-c2c(F)cc(F)cc2F)c1-c1ccc(Cl)cc1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 3/20 0.39
NPC1 O15118 2/20 0.39
TP53 P04637 1/20 0.39
TSHR P16473 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
HSD17B10 Q99714 1/20 0.39
MEN1 O00255 3/20 0.37
KMT2A Q03164 3/20 0.37
MAPT P10636 2/20 0.37
ALDH1A1 P00352 1/20 0.36
HTT P42858 1/20 0.36
PSD A5PKW4 2/20 0.36
IKBKB O14920 1/20 0.36
MAP3K14 Q99558 1/20 0.36
GABRA1 P14867 1/20 0.35
GABRG2 P18507 1/20 0.35
GABRB3 P28472 1/20 0.35
GABRA5 P31644 1/20 0.35
GABRA3 P34903 1/20 0.35
GABRA2 P47869 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3313721 0.94 RAB9A (0.37) RAB9ANPC1TP53TSHRSMN1; SMN2
SCHEMBL14010474 0.92 RAB9A (0.36) RAB9ANPC1TP53TSHRSMN1; SMN2
SCHEMBL1869939 0.92 RAB9A (0.36) RAB9ANPC1TP53TSHRSMN1; SMN2
SCHEMBL2355414 0.87 MEN1 (0.47) RAB9ANPC1TP53TSHRSMN1; SMN2
SCHEMBL3966184 0.86 RAPGEF4 (0.38) RAB9ANPC1SMN1; SMN2MEN1KMT2A
SCHEMBL12457752 0.86 MEN1 (0.37) RAB9ANPC1TP53TSHRSMN1; SMN2
SCHEMBL3303729 0.86 AR (0.36) RAB9ANPC1TP53TSHRSMN1; SMN2
SCHEMBL2356139 0.85 MEN1 (0.36) RAB9ANPC1TP53TSHRSMN1; SMN2
SCHEMBL3332556 0.85 ALDH1A1 (0.34) RAB9ANPC1TP53TSHRSMN1; SMN2
SCHEMBL3339528 0.85 SLC2A1 (0.39) MEN1KMT2AMAPTL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2014166-A1 Active compound combinations Bayer CropScience AG (DE) 2009-01-14 EP claimed
EP-2014165-A1 Active compound combinations Bayer CropScience AG (DE) 2009-01-14 EP claimed
EP-2014167-A1 Active compound combinations Bayer CropScience AG (DE) 2009-01-14 EP claimed
EP-2011397-A1 Active compound combinations Bayer CropScience AG (DE) 2009-01-07 EP claimed
EP-2011396-A1 Active compound combinations Bayer CropScience AG (DE) 2009-01-07 EP claimed
EP-2011395-A1 Active compound combinations Bayer CropScience AG (DE) 2009-01-07 EP claimed
EP-1775290-B1 PYRIDAZINE COMPOUND AND USE THEREOF SUMITOMO CHEMICAL CO (JP) 2010-11-17 EP disclosed
US-7795258-B2 Pyridazine compound and use thereof SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2010-09-14 US disclosed
US-7795258-B2 Pyridazine compound and use thereof SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2010-09-14 US disclosed
EP-2014166-A1 Active compound combinations Bayer CropScience AG (DE) 2009-01-14 EP disclosed
EP-2014167-A1 Active compound combinations Bayer CropScience AG (DE) 2009-01-14 EP disclosed
EP-2014165-A1 Active compound combinations Bayer CropScience AG (DE) 2009-01-14 EP disclosed
EP-2011397-A1 Active compound combinations Bayer CropScience AG (DE) 2009-01-07 EP disclosed
EP-2011396-A1 Active compound combinations Bayer CropScience AG (DE) 2009-01-07 EP disclosed
EP-2011395-A1 Active compound combinations Bayer CropScience AG (DE) 2009-01-07 EP disclosed
US-20080275050-A1 Pyridazine Compound and Use Thereof SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2008-11-06 US disclosed
US-20080275050-A1 Pyridazine Compound and Use Thereof SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2008-11-06 US disclosed
EP-1775290-A1 PYRIDAZINE COMPOUND AND USE THEREOF Sumitomo Chemical Company, Limited (JP) 2007-04-18 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080275050-A1 Pyridazine Compound and Use Thereof CYP4Z1, PNPO, PLPBP RAB9A 1132/4885NPC1 1625/4885TP53 4323/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.